



Academic Program

Reports from the Nordic countries – News and changes:

- Denmark: Christian Langediil Christiansen, Ploughmann & Vingtoft (DK)
- Finland: Linda Norrgård, Boco IP (FI)
- Iceland: Einar Karl Friðriksson, Arnason Faktor (IS)
- Norway: Liv-Heidi Thoresen, Onsagers (NO)
- Sweden: Dan Henriksson, Awapatent (SE)

Preliminary injunctions proceedings in the Nordic countries:

- Preliminary injunctions proceedings in Denmark: Ejvind Christiansen, Zacco (DK) and Casper Struwe, Zacco (DK)
- Preliminary injunctions proceedings in Finland: Christoffer Sundman, Seppo Laine (FI)
- Preliminary injunctions proceedings in Norway: Dorte Lajer, Onsagers (NO)
- Preliminary injunctions proceedings in Sweden: Peter Kenamets, Awapatent (SE)

Patent strategy topics:

- Patent strategy in the pharmaceutical sector – Lundbeck: Morten Rosted, Lundbeck (DK)
- Patent strategy: Antti Kokko, Berggren (FI) and Tomi Nokelainen, Berggren (FI)
- Patent strategy from an industrial perspective: Marianne Freisleben, Novozymes (DK)

Topics re EPO decisions and procedures:

- Partial priority (G 1/15): Kathy Wasström, Seppo Laine (FI)
- 1st and 2nd medical indication: Satu Lehesranta, Papula-Nevinpat (FI)
- Sufficiency of disclosure with focus on chemical EP decisions: Verena Simpson, Guardian IP Consulting (DK) and Lars Pallisgaard Olsen, Guardian IP Consulting (DK)
- Amendments with focus on chemical EP decisions: Einar Karl Friðriksson, Arnason Faktor (IS)
- Defending patents under opposition at the EPO, in the light of “Early certainty from opposition”: Edward Farrington, Inspicos (DK)

Biotechnological topics:

- Patents on plants: Henriette Damsgaard, Budde Schou (DK)
- Patents on plants – from a plant breeders perspective: Rasmus Lund Hjortshøj, Sejet Planteforædling (DK)

SPC topics:

- The SPC regulation and decision from ECJ - seen from the PTO’s point of view: Dorte Krehan Seir Petersen, Danish Patent and Trademark Office (DK)
- SPC situation in Finland: Pirta Tiiri (FI)
- The outcome of the recent EU survey on the SPC system – implications for the pharmaceutical industry: Ulla Klinge, Inspicos (DK)